Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 capsule versus oral suspension relative bioavailability study
NL-OMON45861Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GLPG2737 in cystic fibrosis (CF) (2 arms), sponsored by Galapagos NV. Primary endpoints: Pharmacokinetic parameters of GLPG2737 in plasma and Safety and tolerability assessed by adverse events. Started May 2017; status: active, not recruiting.
02
Drugs
GLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45861.